Fig. 1 PRISMA flow diagram of systematic review evaluating the role of neuromuscular stimulation in venous disease 4 Physical Parameters Comparison between trials is hindered by variations in protocols and…
Compound Dosage Bemiparin 115 IU/Kg/od Dalteparin 200 IU/Kg/od Enoxaparin 100 IU/kg/bid or 150 IU/kg/od Nadroparina 90 IU/Kg/bid or 180 IU/kg/od Reviparin 100 IU/Kg/bid Tinzaparin 175 IU/Kg/od Although in clinical practice UFH has virtually been replaced by LMWHs, we…
Fig. 1 Cumulative incidence of recurrent VTE after the first episode of DVT and/or PE. The incidence of recurrent VTE after discontinuing anticoagulation is twice as high in patients with…
Drug Primary mode of action Metabolism and platelet inhibition Platelet inhibition Dosing Aspirin COX-1 inhibition Prodrug Irreversible Once daily Clopidogrel P2Y12 receptor antagonism Prodrug Irreversible Once daily Prasugrel P2Y12 receptor…
Fig. 1 Virchow’s triad. Rudolph Virchow proposed three major factors that promote abnormal blood clotting 2 Epidemiology Currently, VTE incidence for patients under the age of 18 years is roughly…
Fig. 1 Macroscopic findings: the origin of a thrombus in the popliteal vein (arrow) Fig. 2 Macroscopic findings: pulmonary embolism Usually, the starting point of emboli are leg deep veins,…
Fig. 1 Changes in ambulatory venous pressure [3] The exact cause of venous skin changes and venous ulceration is not yet known although the most prominent theory is that of…
Fig. 1 Anatomy of the normal cerebral venous circulation (Reproduced with kind permission from An Atlas of Neonatal Brain Sonography, 2nd edition, by Paul Govaert and Linda de Vries, published…
Receptor P2Y1 P2Y12 Distribution [6–10] Platelets, heart, blood vessels, smooth muscle cells, connective and neural tissues, testis Platelets, some neural tissues, nasal mucosa, lymphocytes, endothelium G-coupled protein [11, 12] Gq…
Major risk factors Prevalence Inherited Inherited antithrombin deficiency 3.9 %a Inherited protein C deficiency 5.6 %a Inherited protein S deficiency 2.6 %a Factor V Leiden mutation 6 %–32 %b Prothrombin G20210A mutation 14 %–40 %b Acquired Myeloproliferative…
